Partnering

Specialty Pharmaceuticals

BTG develops and commercialises acute care and specialty pharmaceutical products for the treatment of diseases with high unmet medical need. We established our US commercial operations and acute care sales force to promote and sell two critical care products, CroFab^® (crotalidae polyvalent immune fab (ovine)) and DigiFab^® (digoxin immune fab (ovine)).  In addition, we are preparing for the launch of Voraxaze^® (glucarpidase), following recent US regulatory approval. We recently formed a US commercialisation partnership with Wellstat Therapeutics Corporation to exclusively market Wellstat’s investigational antidote, uridine triacetate, following FDA approval.

Partnering Interests
Our Business Development strategy is focused on forming strategic partnerships that complement our expertise in developing and marketing acute care products. We are interested in exploring global and regional partnerships for products within the following areas:

• Marketed products that can be sold through our dedicated hospital-focussed sales force
• Late-stage development programmes that target disease areas treated by specialists with high unmet medical needs
• Medical toxicology and oncology antidotes that complement our commercial and development-stage antidote franchise

For Business Development opportunities within Specialty Pharmaceuticals, please send your enquiries to:
Douglas Carlson, Senior Director of Business Development
BTG International Inc.